The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients

Inclusion Criteria: * Cancer patients with solid tumors under antineoplastic therapy with capecitabine or pegylated liposomal doxorubicin. * Patients with a life expectancy of at least 12 weeks. * History of HFS (grades 2 to 3) in the course of the therapy * Patients who are 18-65 years old. * Regression of HFS to grade 1 or lower with a symmetrical grading on both hands (grade 0 or grade 1) prior to the next cycle of chemotherapy. * not legally incapacitated * Written informed consent from the trial subject has been obtained. * Current treatment with capecitabine or pegylated liposomal doxorubicin Exclusion Criteria: * Persons with any kind of dependency on the investigator or employed by the sponsor or investigator. * Persons held in an institution by legal or official order. * Participation in other interventional trials * Drug \& substance abuse * Use of central nervous depressants (e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics) * Patients taking alpha adrenergic agonists as medication. * Pregnant women and nursing mothers * Failure to use highly-effective contraceptive methods The following contraceptive methods with a Pearl Index lower than 1% are regarded as highly effective: * Oral hormonal contraception ('pill') * Vaginal hormonal contraception (NuvaRing®) * Contraceptive plaster * Long-acting injectable contraceptives * Implants that release progesterone (Implanon®) * Tubal ligation (female sterilization) * Intrauterine devices that release hor…